Reading list
Chemical design, animal absorption and human outcomes occupy different shelves here.
Oral candidate development
The orally active secretagogue series supplies the opening dog bioavailability range. The rat stomach experiment examines a peripheral contribution to hormone release. For the mechanics of redesign, the NN703–ipamorelin hybrids and the conformational-restriction study make a useful pair.
Hormone characterizations
The acute parent-peptide characterization establishes the selective growth-hormone result. The NN703 paper gives the oral derivative its separate absorption and cortisol observations. Side by side, the papers slow my enthusiasm for carrying an adjective from one molecule to another.
Clinical record
The healthy-volunteer study describes intravenous exposure and the hormone pulse. The bowel-resection trial supplies the meal-tolerance outcome and the short safety window. The review of peptide-therapy safety and efficacy provides a wider caution about the human evidence.
- Novel orally active growth hormone secretagogues ↗
- Do growth hormone-releasing peptides act as ghrelin secretagogues? ↗
- Ipamorelin, the first selective growth hormone secretagogue ↗
- Pharmacological characterisation of a new oral GH secretagogue, NN703 ↗
- Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin ↗
- The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency ↗
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers ↗
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients ↗
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance ↗